While prior approaches to the management of LDL plasma concentration aimed towards treating the subjects with dyslipidemia to a target LDL concentration, the latest 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults no longer takes into consideration LDL cut-off concentration but rather identifies groups of patients among whom the benefit of statin outweighs the risk of adverse events.  The 2013 ACC/AHA guidelines identifies the following statin benefit groups: subjects with atherosclerotic cardiovascular disease, subjects with LDL ≥ 190 mg/dL, subjects with diabetes mellitus PLUS age 40-75 years PLUS LDL 10-189 mg/dL, and subjects with LDL 70-189 mg/dL PLUS estimated 10 year risk of atherosclerotic cardiovascular disease ≥ 7.5%.  The pooled cohort equation should be used to estimate the 10 year risk of atherosclerotic cardiovascular disease and guide the treatment among subjects with no diabetes mellitus or atherosclerotic cardiovascular disease.  Lifestyle changes is a critical component of the management of patients with elevated LDL whether they are administered or not lipid lowering drugs.
Low density lipoprotein medical therapy
High density lipoprotein medical therapy
High density lipoprotein future or investigational therapies
Metabolic syndrome dietary therapy
Low density lipoprotein future or investigational therapies
Non-alcoholic fatty liver disease medical therapy
Hemochromatosis medical therapy
Metabolic syndrome medical therapy